Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence ApproachRelease Date:Research Inflammation & Immunology USA Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUCEducation Oncology USA Advancing Genomic Competence and Patient Centered Care in Metastatic Breast CancerRelease Date:Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction ManagementRelease Date:Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positRelease Date:Education Oncology United States Minor Outlying I OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic MalignanciesRelease Date:Quality Improvement Oncology China Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory OutcomeRelease Date:Education Vaccines USA Implementing Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Fellowship Internal Medicine Germany Title Grant Type Focus Area Country Application Due Date Enhancing HCPs’ Preparedness: Maternal Immunization Knowledge UpdatesRelease Date:Education Vaccines USA Real-World Clinical Outcomes Among Adult and Adolescent Patients with Severe Alopecia Areata Receiving Ritlecitinib in ChinaRelease Date:Research Inflammation & Immunology China Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic BladderRelease Date:Education Internal Medicine Japan Interventional Research Studies with ElranatamabRelease Date:Research Oncology All Research in Ulcerative Colitis (UC) 2024Release Date:Research Inflammation & Immunology Brazil, India, Mexico, Saudi Arabia, Taiwan, Turkey Advances in the Management of Ulcerative Colitis (UC)Release Date:Education Inflammation & Immunology All Research in Ulcerative Colitis (UC) 2024Release Date:Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology USA BCMA-Directed Bispecific Antibody Treatment in Multiple MyelomaRelease Date:Education Oncology Japan Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophiliaRelease Date:Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)Release Date:Education Rare Disease All Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)Education Oncology USA